Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION
1985567 citationsM Verstraete, D P de Bono et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of M Verstraete's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Verstraete with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Verstraete more than expected).
This network shows the impact of papers produced by M Verstraete. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Verstraete. The network helps show where M Verstraete may publish in the future.
Co-authorship network of co-authors of M Verstraete
This figure shows the co-authorship network connecting the top 25 collaborators of M Verstraete.
A scholar is included among the top collaborators of M Verstraete based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with M Verstraete. M Verstraete is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Close, Philippe, J. Bichler, Roger Kerry, et al.. (1994). Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).. PubMed. 5(11). 943–9.33 indexed citations
Collen, Désiré, B Wiman, & M Verstraete. (1979). The physiological inhibitors of blood coagulation and fibrinolysis : proceedings of a round-table conference held at the University of Leuven, Belgium, July 22-23, 1978. Elsevier eBooks.4 indexed citations
17.
Verstraete, M. (1978). [The interaction between drugs and oral anticoagulants of the coumarin group].. Library Stack (Library Stack). 54(13-16). 505–8.
Donati, Maria Benedetta, Giovanni de Gaetano, J. Vermylen, & M Verstraete. (1972). Il "fibrin polymerization time (FPT)-test": un metodo rapido, semplice e sensibile per la determinazione della fibrinogenemia.. Il Farmaco. 27(4). 214–224.
20.
Verstraete, M & Jan P. Vandenbroucke. (1955). Thrombocytopénies par agglutinines; revue du problème et présentation de nouveaux cas.. Acta Haematologica. 13(3).1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.